BrainChild Bio Introduces Breakthrough B7-H3 CAR T-Cell Therapy for Diffuse Intrinsic Pontine Glioma
BrainChild Bio has introduced BCB-276, an investigational B7-H3 targeting CAR T-cell therapy for the treatment of diffuse intrinsic pontine glioma (DIPG), a rare and fatal paediatric brain tumour.
BCB-276 is designed to deliver autologous CAR T-cells directly into the cerebrospinal fluid, targeting the B7-H3 antigen commonly found in CNS tumours. The therapy uses intracerebroventricular (ICV) administration through an implanted reservoir-catheter device, enabling repeat infusions and sustained exposure to the tumour site.
The unique anatomical location, invasive tumour growth, and an intact blood-brain barrier have posed major challenges to delivering effective treatments for DIPG.
CAR T-cell therapies like BCB-276 may offer a new approach by overcoming these barriers through locoregional delivery. This strategy enhances tumour exposure while minimising systemic toxicity and reducing off-target effects.
At present, no approved therapies directly target DIPG in a way that addresses the biological and anatomical complexities of the disease.
DIPG is a high-grade glioma located in the brainstem, specifically the pons, and typically affects children between the ages of five and ten. It accounts for approximately 300 diagnoses annually in the United States. Current treatments remain limited to palliative radiation therapy, with a median overall survival of about 11 months.
BCB-276 is the first and only investigational CAR T-cell therapy to receive U.S. FDA Breakthrough Therapy designation for the treatment of diffuse intrinsic pontine glioma (DIPG) in children.
